## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner:

McDOWELL, B.

KUBO et al.

Applicant:

(CHECK ONE):

10/535268 Group Art Unit: 1624 Serial No.: Filed: March 21, 2006 Docket: 8279.1210USWO IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE Title: CERTIFICATE OF TRANSMISSION Thereby certify that this paper is being transmitted by EFS Web to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on I DECEMBER 2009. SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir: With regard to the above-identified application, the items of information listed on

the enclosed Form SB08 are brought to the attention of the Examiner. Copies of any foreign patent documents or "Other Documents" are enclosed.

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed

□ (1) within three (3) months of the Filing Date, before the mailing date of a First Office Action on the merits, or before the mailing date of a First Office Action on the merits after the filing of a request for continued examination under 37 C.F.R. §1.114; or

② (2) after the period defined in (1) but before the mailing date of a Final Rejection or Notice of Allowance, and

□ the requisite Statement is below, OR

③ the requisite fee of \$180.00 under Rule 1.17(p) is included herein, or

□ (3) after the mailing date of a Final Rejection or Notice of Allowance but on or before the payment of the Issue Fee, AND the requisite Statement is below

AND the requisite fee of \$180.00 under Rule 1.17(p) is included herein.

## STATEMENT

Applicants hereby state that:				
		Statement was first in a counterpart app	lication or by the USPTO oths prior to the filing date	from a foreign patent office in a related application not
	If this box is checked, Applicant provides the following:			
Certification Under 37 C.F.R. §1.704(d)				
	In accordance with 37 C.F.R. §1.704(d), the undersigned hereby certifies that each item listed on the enclosed Form SB08 was first cited in a communication from a foreign patent office in a counterpart application, and that this communication was not received by any individual designated in 37 C.F.R. §1.56(c) more than thirty (30) days prior to the filling of this Information Disclosure Statement.			
	The Examiner is hereby advised of the following co-pending U.S. applications. A ppy of each U.S. patent application publication (if published) or application (if not blished) is enclosed.			
	Apr	lication No.	Filing Date	Group

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form SB08, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

## FEE AUTHORIZATION

Please charge any required fee or credit overpayment to Deposit Account No. 50-3478.

Respectfully submitted,

HAMRE, SCHUMANN, MUELLER & LARSON, P.C. P.O. Box 2902 Minneapolis, MN 55402-0902

(612) 455-3800

Bv:

Dated: 1 December 2009

Douglas P. Mueller Reg. No. 30,300

DPM:hjm